JP MORGAN/CALL/ELI LILLY & CO/1330/0.01/20.06.25 | Real-time Bid/Ask 07:01:30 2024-06-04 am EDT | ||
| 0.15 EUR / 0.17 EUR | +14.29% |
|
| Current month | -17.65% | ||
| 1 month | +59.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-06-04 | 0.16 | +14.29% |
| 24-06-03 | 0.14 | -17.65% |
| 24-05-31 | 0.17 | 0.00% |
| 24-05-30 | 0.17 | +6.25% |
| 24-05-29 | 0.16 | 0.00% |
Delayed Quote Börse Stuttgart
Last update June 04, 2024 at 03:39 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK6Y0U |
| ISIN | DE000JK6Y0U8 |
| Date issued | 2024-04-09 |
| Strike | 1,330 $ |
| Maturity | 2025-06-20 (382 Days) |
| Parity | 100 : 1 |
| Emission price | 0.14 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.18 € |
|---|---|
| Lowest since issue | 0.087 € |
| Spread | 0.02 € |
| Spread % | 11.11% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
831.3
USD
Average target price
852.5
USD
Spread / Average Target
+2.56%
- Stock Market
- Warrants
- Warrant
